米吉珠单抗治疗中重度斑块状银屑病的II期随机试验
第16周时,各米吉珠单抗剂量组PASI 90应答率均显著优于安慰剂,300mg组达67%,安全性与安慰剂相似。
要点
- 米吉珠单抗300mg组第16周PASI 90应答率达67%,显著优于安慰剂。
- 各剂量组PASI 90应答率随剂量增加而升高,呈剂量依赖性。
- 治疗中出现的不良事件发生率在安慰剂组和米吉珠单抗组相似。
核心结论
- 米吉珠单抗30mg、100mg、300mg组第16周PASI 90应答率均显著优于安慰剂,300mg组达67%。
- 米吉珠单抗治疗中出现至少一次不良事件的患者比例与安慰剂组相似。
研究设计与样本
- 多中心、双盲、随机、安慰剂对照II期试验(AMAF;NCT02899988)。
- 成人中重度斑块状银屑病患者按1:1:1:1随机分配至安慰剂(n=52)、米吉珠单抗30mg(n=51)、100mg(n=51)或300mg(n=51)组,第0、8周皮下给药。
- 主要终点为第16周达到PASI 90应答的优效性比较,采用逻辑回归分析,缺失数据按无应答处理。
主要发现
- 米吉珠单抗治疗组发生2例(1%)严重不良事件,安慰剂组发生1例(2%)。
关键数值与推荐
- 主要终点:第16周PASI 90应答率。
临床怎么用
- 米吉珠单抗300mg每8周皮下注射可在第16周使67%的中重度斑块状银屑病患者达到PASI 90。
- 米吉珠单抗的安全性与安慰剂相似,未观察到新的安全性信号。
局限性
- 本研究为II期试验,样本量较小,长期疗效和安全性需进一步验证。
- 研究仅评估了16周内的疗效和安全性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Inhibiting interleukin (IL)-23 in patients with psoriasis has demonstrated high levels of skin clearance. OBJECTIVES: To investigate, in a phase II (AMAF; NCT02899988), multicentre, double-blind trial, the efficacy and safety of three doses of mirikizumab (LY3074828), a p19-directed IL-23 antibody, vs. placebo in patients with moderate-to-severe plaque psoriasis. METHODS: Adult patients were randomized 1 : 1 : 1 : 1 to receive placebo (n = 52), mirikizumab 30 mg (n = 51), mirikizumab 100 mg (n = 51) or mirikizumab 300 mg (n = 51) subcutaneously at weeks 0 and 8. The primary objective was to evaluate the superiority of mirikizumab over placebo in achieving a 90% improvement in the Psoriasis Area and Severity Index (PASI 90) response at week 16. Comparisons were done using logistic regression analysis with treatment, geographical region and previous biological therapy in the model. Missing data were imputed as nonresponses. RESULTS: Ninety-seven per cent of patients completed the first 16 weeks of the study. The primary end point was met for all mirikizumab dose groups vs. placebo, with PASI 90 response rates at week 16 of 0%, 29% (P = 0·009), 59% (P < 0·001) and 67% (P < 0·001) for patients receiving placebo, and mirikizumab 30 mg, 100 mg and 300 mg, respectively. There were two (1%) serious adverse events in mirikizumab-treated patients vs. one (2%) in a placebo-group patient. CONCLUSIONS: At week 16, 67% of patients treated with mirikizumab 300 mg at 8-week intervals achieved PASI 90. The percentage of patients reporting at least one treatment-emergent adverse event was similar among patients treated with placebo or mirikizumab.
引用
- Reich K, Rich P, Maari C, et al. Efficacy and safety of mirikizumab (LY3074828) in the treatment of moderate-to-severe plaque psoriasis: results from a randomized phase II study. Br J Dermatol. 2019. PMID: 30734266. doi:10.1111/bjd.17628
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。